Readers discuss cholesterol treatments and AI

Cover of the January 27, 2024 issue of Science News

Get low (cholesterol’s version)

An experimental genetic treatment called VERVE-101 can deactivate a cholesterol-raising gene in people with hypercholesterolemia, Meghan Rosen reported in “Base editing can lower cholesterol” (SN: 1/27/24, p. 8).

Rosen wrote that researchers are testing to see what dosage of VERVE-101 is most effective. Given that the treatment edits a gene, reader Linda Ferrazzara wondered why the dose matters.

Too low a dose may mean that not enough VERVE-101 makes it to the liver, where it turns off the gene, Rosen says. If too few cells have the gene switched off, patients will not experience the drug’s cholesterol-lowering effects.

Read this story for free

Enter your email address for continued access to Science News

By continuing, you acknowledge that you are at least 13 years of age and agree to the Terms of Service and Privacy Policy.  Under 13?  Check out Science News Explores.

 

OR
Use up and down arrow keys to explore.Use right arrow key to move into the list.Use left arrow key to move back to the parent list.Use tab key to enter the current list item.Use escape to exit the menu.Use the Shift key with the Tab key to tab back to the search input.